Received July 19, 2022
Accepted December 02, 2022

Objective: To determine embryos viability in preimplantation genetic diagnosis by Fluorescent In Situ Hybridization or Comparative Genomic Hybridization. Methods: Were biopsied 57 embryos from patients with clinical cases and similar age. Of these, 13 had DNA degraded/ absent, 17 were analyzed by Comparative Genomic Hybridization, 18 by Fluorescent In Situ Hybridization with 11 probes and 9 with 9 probes. We analyzed the percentage of aneuploids results that could have been obtained by each technique. Results: Among embryos diagnosed with aneuploidy by Fluorescent In Situ Hybridization with 9 probes, 60% could be diagnosed using 5 or 7 probes. The results of the method with 11 probes indicated that 80% of embryos with aneuploidy could have been diagnosed by 5 probes, 86.7% through the use of 7 probes and 100% with 9 probes. In relation to Comparative Genomic Hybridization, could have been diagnosed 53.8% of aneuploid embryos by 5 probes, 69,2% by 7 probes and 84,6% using 9 or 11 probes. Conclusions: Diagnosis by Comparative Genomic Hybridization provides more accurate results. Its indication for patients with recurrent implantation failure and maternal advanced age should be considered because allowing the selection of best embryos. However, our data demonstrate that diagnosis by Fluorescent In Situ Hybridization may be sufficient to identify the most cases of aneuploidies, without need for further investment. Is important emphasize that the sample size is still small, so the study will continue to obtain more conclusive results.